[P68] ポスターセッション 68　臨床試験推進プログラム

[P68-1] Phase 3 Trial（EPCORE DLBCL-1）of Epcoritamab vs Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

^○Christopher P. Fox¹, Michael Roost Clausen², Pieternella Lugtenburg³, Anna Sureda⁴, Pier Luigi Zinzani⁵, Jun Wu⁶, Laura Finn⁷, Signe Diness Vindeløv⁸, Catherine Thieblemont⁹ (1.Nottingham University Hospitals NHS Trust UK, Nottingham, UK, 2.Vejle Hospital, Vejle, Denmark, 3.On behalf of the HOVON Lymphoma Working Group, Erasmus MC Cancer Institute, Department of Hematology, Rotterdam, Netherlands, 4.Institut Català d’Oncologia, Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain, 5.Lymphoma and Chronic Lymphoproliferative Syndromes Unit, Institute of Hematology “L. e A. Seràgnoli,” University of Bologna, Bologna, Italy, 6.AbbVie, North Chicago, IL, USA, 7.Ochsner Medical Center, New Orleans, LA, USA, 8.Genmab A/S, Copenhagen, Denmark, 9.Assistance Publique & Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Hémato-oncologie, Université de Paris, Paris, France)